Phase 3 Trial to Evaluate the Efficacy and Safety of YYC506.

• Status: Recruiting
• Trial end date: 2022-01-31
• Target enrollment: 0
• Participant gender: All

Summary

Phase 3 study to evaluate the effiacay and safety of YYC506

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yooyoung Pharmaceutical Co., Ltd.

Criteria

Inclusion Criteria:

• A man or woman over 19 years old.

• LDL-C properly controlled, TG, HDL-C is not properly controlled

• Sign on ICF prior to study participation

Exclusion Criteria:

• History of Fibromyalgia, Myopathy etc (CK ≥ 2XULN)

• Uncontrolled hypo-thyroidism (TSH≥1.5XULN)

• Severe renal impairemnet (Creainine clearance < 30mL/min) etc.